8 November 2021 in PLOS Computational Biology
Genome-scale metabolic models (GEMs) are comprehensive knowledge bases of cellular metabolism and serve as mathematical tools for studying biological phenotypes and metabolic states or conditions in various organisms and cell types. Given the sheer size and complexity of human metabolism, selecting parameters for existing analysis methods such as metabolic objective functions and model constraints is not straightforward in human GEMs. In particular, comparing several conditions in large GEMs to identify condition- or disease-specific metabolic features is challenging. In this study, we showcase a scalable, model-driven approach for an in-depth investigation and comparison of metabolic states in large GEMs which enables identifying the underlying functional differences. Using a combination of flux space sampling and network analysis, our approach enables extraction and visualisation of metabolically distinct network modules. Importantly, it does not rely on known or assumed objective functions. We apply this novel approach to extract the biochemical differences in adipocytes arising due to unlimited vs blocked uptake of branched-chain amino acids (BCAAs, considered as biomarkers in obesity) using a human adipocyte GEM (iAdipocytes1809). The biological significance of our approach is corroborated by literature reports confirming our identified metabolic processes (TCA cycle and Fatty acid metabolism) to be functionally related to BCAA metabolism. Additionally, our analysis predicts a specific altered uptake and secretion profile indicating a compensation for the unavailability of BCAAs. Taken together, our approach facilitates determining functional differences between any metabolic conditions of interest by offering a versatile platform for analysing and comparing flux spaces of large metabolic networks.
1 December 2021 in bioRxiv
Analysis of the genes retained in the minimized Mycoplasma JCVI-Syn3A genome established that systems that repair or preempt metabolite damage are essential to life. Several genes with known metabolite damage repair or preemption functions were identified and experimentally validated, including 5-formyltetrahydrofolate cyclo-ligase, CoA disulfide reductase, and certain hydrolases. Furthermore, we discovered that an enigmatic YqeK hydrolase domain fused to NadD has a novel proofreading function in NAD synthesis and could double as a MutT-like sanitizing enzyme for the nucleotide pool. Finally, we combined metabolomics and cheminformatics approaches to extend the core metabolic map of JCVI-Syn3A to include promiscuous enzymatic reactions and spontaneous side reactions. This extension revealed that several key metabolite damage-control systems remain to be identified in JCVI-Syn3A, such as that for methylglyoxal.
1 August 2026 in Circulation: Genomic and Precision Medicine
BACKGROUND: Dilated cardiomyopathy (DCM) is associated with shifts in cardiac metabolism. However, those shifts vary widely across patients, likely reflecting the diverse underlying causes of the disease. Identifying metabolic subtypes, or metabotypes, in DCM patients could help tailor treatments to patient needs. Hence, having a practical approach to identify these metabotypes would be a significant advance toward precision medicine in DCM. METHODS: We present a systems biology approach to uncover metabotypes directly from widely available transcriptomic data. We use in silico metabolic modeling methods that we have optimized for cardiac research to predict metabolic function activities from enzyme expression, followed by a hierarchical clustering approach. To demonstrate its power, we applied our method to publicly available cardiac data from end-stage DCM patients (N=164) and nonfailing controls (N=160). RESULTS: We identified 2 distinct metabotypes in end-stage DCM patients. These metabotypes are characterized by unique metabolic changes, notably in calcium handling, amino acid oxidation, and the pentose phosphate pathway. Strikingly, 1 DCM metabotype showed greater metabolic divergence from healthy controls, suggesting a greater metabolic contribution to its underlying etiology—even though disease severity was similar between the 2 identified DCM metabotypes. Further transcriptome-wide analysis revealed immune-related differences between metabotypes, suggesting an underlying interplay between inflammation, the immune response, and metabolism. CONCLUSIONS: Our results imply the presence of distinct metabotypes in end-stage DCM. Our systems biology approach offers an exciting opportunity to uncover novel insights into DCM, paving the way for a deeper understanding of its progression and heterogeneity.